97300 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Agonist effect on antigen
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
#1202Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
#1203Humanized or chimeric CD3 antibodies
#1204Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
#1205Cell compositions and methods for cancer therapy
#1206RNA containing composition for treatment of tumor diseases
#1207Targeting WSB1 and pVHL to treat cancer
#1208Methods, kits and devices for promoting cardiac regeneration
#1209Treatment of celiac disease, C. difficile infection, food intolerance and food allergy with secretory IgA/IgM
#1210Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1211MET-BINDING AGENTS AND USES THEREOF
#1212Anti-PD-1 antibodies
#1213Anti-CD40 antibodies
#1214METHODS FOR TREATING ALLERGIC AIRWAY INFLAMMATION
#1215Antibodies to ICOS
#1216Anti-DR6 antibodies and methods of immune regulation
#1217METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT
#1218Regulating Bacillus anthracis lethal factor activity via an activating epitope region
#1219Antibodies directed against ICOS and uses thereof
#1220Method for generation of immunoglobulin sequences
#1221Antibody therapeutics that bind TIM3
#1222Anti-PD-1 antibodies
#1223Vector co-expressing vaccine and costimulatory molecules
#1224Antibody therapeutics that bind CD137
#1225Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide
#1226Antibodies against human CD38
#1227ANTI-TWEAKR ANTIBODIES AND USES THEREOF
#1228Vectors for expression of prostate-associated antigens
#1229Methods of treatment that include the administration of bispecific antibodies
#1230ICOS binding proteins
#1231Human immune therapies using a CD27 agonist in combination with another immune agonist to treat cancer
#1232METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING METALLOTHIONEINS
#1233Anti-CD40 antibodies
#1234Methods Of Identifying Anti-Inflammatory Compounds
#1235ANTIBODIES THAT INHIBIT TIM-3:LILRB2 INTERACTIONS AND USES THEREOF
#1236Modulation of tumor immunity
#1237Inotropic antibodies and therapeutic uses thereof
#1238Modulation of γδ T cells
#1239Screening method for inhibitors of binding of zBR7R1 to CD155
#1240Anti-LRP5 antibodies and methods of use
#1241SYSTEMS AND METHODS FOR ASSESSING MODULATORS OF IMMUNE CHECKPOINTS
#1242Pharmaceutical compositions containing sc(Fv)2
#1243ANTIBODIES FOR GUANYLYL CYCLASE RECEPTORS
#1244Anti-FGFR3 antibodies and methods using same
#1245Humanized or chimeric CD3 antibodies
#1246ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
#1247METHODS AND BIOMARKERS FOR PREDICTING EFFICACY AND EVALUATION OF AN OX40 AGONIST TREATMENT
#1248Humanized antibodies with ultralong complementary determining regions
#1249Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
#1250Adjuvant combinations comprising alpha-galactosylceramide or iGb3, CD40 agonists and antigen
#1251COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND TIGIT INHIBITORS
#1252Compositions and methods related to structures that cross the blood brain barrier
#1253CADHERIN 15 AGONISTS
#1254Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
#1255Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#1256IL-21 binding proteins
#1257AGONISTIC ANTIBODIES TO TRKC RECEPTORS AND USES THEREOF
#1258ANTIBODIES AND OTHER MOLECULES THAT BIND B7-H1 AND PD-1
#1259Fc-free antibodies comprising two fab-fragments and methods of use
#1260COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#1261Isolated antibody
#1262Anti-ROBO4 antibody
#1263Anti-CD19 scFv (FMC63) polypeptide
#1264NOVEL ANTIBODIES
#1265Methods for enhancing anti-tumor antibody therapy
#1266CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
#1267VISTA Antagonist and Methods of Use
#1268Sodium pump antibody agonists and methods of treating heart disease using the same
#1269DNA encoding an anti-CD40 IgG2 antibody having amino acid mutations
#1270Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#1271Nucleic acid encoding anti-OX40 antibodies
#1272FDF03 ANTIBODIES AND USES THEREOF
#1273PD-1 antibodies
#1274Markers of acute myeloid leukemia stem cells
#1275MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF
#1276IN VITRO SYSTEM FOR GENERATION OF ANTIGEN-SPECIFIC IMMUNE RESPONSES
#1277Heterodimeric immunoglobulins
#1278Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
#1279Method of reducing blood glucose by administering RON agonists
#1280Anti-H7CR antibodies
#1281Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#1282Modulators
#1283Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#1284Methods of controlling parasitic worms in animals
#1285FGFR1 agonists and methods of use
#1286Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
#1287Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
#1288Anti-GITR antibodies and methods of use thereof
#1289MUSCARINIC ACETYLCHOLINE RECEPTOR BINDING AGENTS AND USES THEREOF
#1290Methods for expansion or depletion of T-regulatory cells
#1291Composition comprising a TNFR agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma
#1292Human anti TSHR antibodies
#1293Antibody Fc mutants with ablated effector functions
#1294Inert format
#1295Antibodies that bind human CD27 and uses thereof
#1296Humanized or affinity-matured anti Ang-2 antibody and uses thereof
#1297COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESIS
#1298Modulators
#1299Methods and compositions related to modulators of eukaryotic cells
#1300Anti-OX40 antibodies and methods of using the same
#1301Anti-OX40 antibodies and methods of use
#1302Compositions and methods including a recombinant human MAB that promotes CNS remyelination
#1303Sodium pump antibody agonists and methods of treating heart disease using the same
#1304Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia
#1305METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING IL-27 INDUCED PATHWAYS
#1306COMPOSITIONS AND METHODS FOR MODULATING CELL SIGNALING
#1307lipopolysaccharide outer core epitope
#1308HETERODIMER BINDING PROTEINS AND USES THEREOF
#1309THERAPEUTIC CD47 ANTIBODIES
#1310METHODS FOR ACCELERATING IMMUNE REGENERATION
#1311Methods of inhibiting platelet aggregation and preventing thrombosis using antibodies that bind (Na+K)-ATPase β subunit
#1312GITR antibodies and methods of inducing or enhancing an immune response
#1313Antibodies directed to IL-17A/IL-17F heterodimers
#1314Combination therapy with an anti-ANG2 antibody and a CD40 agonist
#1315USP2A PEPTIDES AND ANTIBODIES
#1316Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor
#1317Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1318Compositions and methods for detecting, treating and preventing diseases and disorders
#1319Beta klotho binding proteins and methods of use thereof
#1320Human antibodies to PD-L1
#1321Inotropic antibodies and therapeutic uses thereof
#1322Dimeric protein with triple mutations
#1323Fusion polypeptides capable of activating receptors
#1324METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER
#1325Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
#1326APELIN PEPTIDES, ANTIBODIES THERETO, AND METHODS OF USE
#1327THERAPEUTIC STRATEGY FOR TREATING AUTOIMMUNE AND DEGENERATIVE DISEASES
#1328FDF03 ANTIBODIES AND USES THEREOF
#1329Anti-ROBO4 antibody
#1330Cancer treatment and monitoring methods using OX40 agonists
#1331Use of an anti-Ang2 antibody
#1332Alpha B-Crystallin as a Therapy for Ischemia or Inflammation
#1333Method of treating motor neuron disease with an antibody that agonizes MuSK
#1334CYCLON EXPRESSION FOR THE IDENTIFICATION AND CONTROL OF CANCER CELLS
#1335Method of blocking vascular leakage using an anti-ANG2 antibody
#1336Anti-Ang2 antibody
#1337Modulation of TIM receptor activity in combination with cytoreductive therapy
#1338Methods of promoting immunity to an infectious agent by administering CD40 agonists and alpha-galactosyl ceramide
#1339Surrogate binding proteins which bind DR4 and/or DR5
#1340Humanized anti-CD134 (OX40) antibodies and uses thereof
#1341USES OF MAMMALIAN CYTOKINES AND AGONISTS; RELATED REAGENTS
#1342Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
#1343Anti-LRP6 antibodies
#1344KLOTHO BETA
#1345Treatment of food intolerance and food allergy with IgM
#1346Anti-CD40 antibodies and methods of treating cancer
#1347Monoclonal antibodies to Programmed Death 1 (PD-1)
#1348Anti-glucagon antibodies and uses thereof
#1349Immune modulation via C-type lectin
#1350Methods for treating cancer using anti-PD-1 antibodies
#1351Biological materials and uses thereof
#1352Compositions and methods for diagnosis and treatment of hepatic cancers
#1353Anti-OX40 antibodies and methods of treating cancer
#1354Antagonistic DR3 ligands
#1355Monoclonal antibodies to programmed death 1 (PD-1)
#1356Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment
#1357Notch agonists for the treatment of cancer
#1358Use of anti-CD83 agonist antibodies for treating autoimmune diseases
#1359Human monoclonal antibodies and methods for producing the same
#1360JAML specific binding agents, antibodies, and uses related thereto
#1361Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#1362Humanized anti-HLA-DR antibodies
#1363Monovalent binding proteins
#1364Activation of sodium potassium ATPase
#1365Methods of modulating HVEM, BTLA and CD160 cis complex response or signaling activity with soluble light polypeptide sequences
#1366Therapeutic agent for autoimmune diseases comprising PD-1 agonist
#1367Variants of humanized immunomodulatory monoclonal antibodies
#1368Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies
#1369Actriia binding agents and uses thereof
#1370DDR1-binding agents and methods of use thereof
#1371Anti-c-Met antibody having HGF activity and use thereof
#1372Fully human antibodies against human 4-1BB
#1373Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
#1374Method for making pluripotent stem cells
#1375Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
#1376Heterodimeric immunoglobulins
#1377EPHB3-specific antibody and uses thereof
#1378Anti-Notch3 antibodies and antibody-drug conjugates
#1379Anti-CD40 antibodies and methods of use
#1380Generation of new pancreatic beta cells
#1381VISTA modulators for diagnosis and treatment of cancer
#1382Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
#1383Antibodies directed against ICOS and uses thereof
#1384Antibody specifically recognizing an epitope for switching to Th2 cell and a method for converting T cell to type 2 helper T cell using the same
#1385Monoclonal antibody specifically recognizing an epitope for switching to Th17 cell
#1386Antibody specifically recognizing an epitope for switching to T1 cell
#1387Method of treating hypertension disorder and a pharmaceutical agent
#1388Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
#1389Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
#1390Agonistic antibodies to TrkC receptors and uses thereof
#1391B-cell reduction using CD37-specific and CD20-specific binding molecules
#1392Method of producing a positive inotropic effect using an antibody that binds sodium potassium atpase
#1393Antagonistic DR3 ligands
#1394Antagonistic DR3 ligands
#1395Bispecific antibodies
#1396Anti-TLR4 antibodies and uses thereof
#1397Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
#1398CD89 activation in therapy
#1399Antibody to human IL-3 receptor alpha chain
#1400Anti-FGFR3 antibodies and methods using same
#1401Anti-OX40 antibodies and methods of using the same
#1402Preparation of isolated agonist anti-EDAR monoclonal antibodies
#1403FN14 binding proteins and uses thereof
#1404Recombinantly produced antibody
#1405Humanized anti-CDCP1 antibodies
#1406Antibodies against human CD38
#1407Agonistic antibody to CD27
#1408Protein binding domains stabilizing functional conformational states of GPCRs and uses thereof
#1409Humanized antibodies to iNKT
#1410Epitopes of the human PDGF receptor able to bind human auto-antibodies, antibodies and uses thereof
#1411Human FGF receptor and β-Klotho binding proteins
#1412Treatment of ocular disease
#1413PD-1 antibody
#1414Anti c-Met humanized antibody and uses thereof
#1415ENHANCED DEATH RECEPTOR AGONISTS
#1416Anti-FGFR3 antibodies and methods using same
#1417Fusion polypeptides capable of activating receptors
#1418Fusion polypeptides capable of activating receptors
#1419ANTIBODIES TO CD40
#1420Variants of humanized immunomodulatory monoclonal antibodies
#1421Methods of making and using multispecific antibody panels and antibody analog panels
#1422Injectable solution containing therapeutic agent for osteoarthritis
#1423Broadly cross-reactive HIV-1 Env-specific antibodies
#1424Targeting cancer stem cells with DR5 agonists
#1425Agents for treating disease
#1426Medical methods and agents for use therein
#1427Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
#1428Compositions and Methods for Treating Inflammatory Lung Disease
#1429Methods for enhancing anti-tumor antibody therapy
#1430Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#1431Antibodies to c-Met
#1432CRYSTAL STRUCTURES AND METHODS USING SAME
#1433Anti-CD40 antibodies
#1434lipopolysaccharide outer core epitope
#1435FGFR1 agonists and methods of use
#1436Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
#1437METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER
#1438Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
#1439FDF03 ANTIBODIES AND USES THEREOF
#1440Monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
#1441Combination immunotherapy for the treatment of cancer
#1442Modified antibody constant regions
#1443Antibody Substituting for Function of Blood Coagulation Factor VIII
#14444-1BB binding molecules
#1445Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
#1446COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#1447ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES
#1448Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44
#1449Sodium pump antibody agonists and methods of treating heart disease using the same
#1450Preparation of isolated agonist anti-EDAR monoclonal antibodies
#1451Sp35 antibodies and uses thereof
#1452Vaccine targeting cellular death receptor DR5
#1453MDL-1 USES
#1454Luminescent porous silicon nanoparticles for targeted delivery and immunization
#1455lipopolysaccharide outer core epitope
#1456Modulation of TIM receptor activity in combination with cytoreductive therapy
#1457Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof
#1458Methods for treating inflammation using B7-H4 polypeptides and fragments thereof
#1459Fully human antibodies against human 4-1BB
#1460Virus vaccination and treatment methods with OX40 agonist compositions
#1461Method for in vivo expansion of T regulatory cells
#1462MODULATION OF PILR RECEPTORS TO TREAT MICROBIAL INFECTIONS
#1463MODULATION OF PILR RECEPTORS TO TREAT SEPSIS
#1464ACTRIIA BINDING AGENTS AND USES THEREOF
#1465THERAPEUTIC COMPOSITIONS AND METHODS
#1466Antibodies for guanylyl cyclase receptors
#1467CD86 antagonist multi-target binding proteins
#1468Agonistic anti-CD40 IGG2 antibodies having amino acid mutations introduced therein
#1469Methods and compositions for the generation and maintenance of regulatory T cells
#1470Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
#1471Antibody to human IL-3 receptor alpha chain
#1472Methods for treating IgE-mediated disorder
#1473Antibodies that bind alpha subunit of sodium potassium ATPase
#1474IL-1F5 polypeptides
#1475Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
#1476Antibodies That Specifically Bind to DR3
#1477METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM
#1478Antibodies to insulin-like growth factor I receptor
#1479Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
#1480Perlecan domain V protects, repairs and restores ischemic brain stroke injury and motor function
#1481Human monoclonal antibodies and methods for producing the same
#1482Biologic compounds directed against death receptor 5
#1483Alpha B-crystallin as a therapy for ischemia or inflammation
#1484IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
#1485Sp35 Antibodies and Uses Thereof
#1486DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT
#1487Treatment of celiac disease with IgA
#1488Human anti TSHR antibodies
#1489DDR1-binding agents and methods of use thereof
#1490AGONIST ANTI-TRKC ANTIBODIES AND METHODS USING SAME
#1491TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES
#1492Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta)
#1493Antibodies that bind human CD27 and uses thereof
#1494Process for the modulation of the antagonistic activity of a monoclonal antibody
#1495Biological materials and uses thereof
#1496Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies
#1497Anti-LRP6 antibodies
#1498Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
#1499Antibodies to LRP6
#1500IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS